Research Advances on Probiotics-assisted Therapy for Metabolic Dysfunction-Associated Fatty Liver Disease

Jia XIONG; Jia ZENG; Xiaoxian ZHOU; Xin XU; Yanjiao WANG; Zhishuang WU; Jianzhong YIN; Fei MI

doi:10.12259/j.issn.2095-610X.S20250720

Volume 46 Issue 7

Jul. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > 46(7): 163-174

Jia XIONG, Jia ZENG, Xiaoxian ZHOU, Xin XU, Yanjiao WANG, Zhishuang WU, Jianzhong YIN, Fei MI. Research Advances on Probiotics-assisted Therapy for Metabolic Dysfunction-Associated Fatty Liver Disease[J]. Journal of Kunming Medical University, 2025, 46(7): 163-174. doi: 10.12259/j.issn.2095-610X.S20250720

Citation:

Jia XIONG, Jia ZENG, Xiaoxian ZHOU, Xin XU, Yanjiao WANG, Zhishuang WU, Jianzhong YIN, Fei MI. Research Advances on Probiotics-assisted Therapy for Metabolic Dysfunction-Associated Fatty Liver Disease[J]. Journal of Kunming Medical University, 2025, 46(7): 163-174. doi: 10.12259/j.issn.2095-610X.S20250720

Citation:

Jia XIONG, Jia ZENG, Xiaoxian ZHOU, Xin XU, Yanjiao WANG, Zhishuang WU, Jianzhong YIN, Fei MI. Research Advances on Probiotics-assisted Therapy for Metabolic Dysfunction-Associated Fatty Liver Disease[J]. Journal of Kunming Medical University, 2025, 46(7): 163-174. doi: 10.12259/j.issn.2095-610X.S20250720

PDF( 1195 KB)

Research Advances on Probiotics-assisted Therapy for Metabolic Dysfunction-Associated Fatty Liver Disease

doi: 10.12259/j.issn.2095-610X.S20250720

Jia XIONG^{1, 2
,},
Jia ZENG^{1, 2},
Xiaoxian ZHOU²,
Xin XU^{1, 2},
Yanjiao WANG^{1, 2},
Zhishuang WU²,
Jianzhong YIN^{1, 2
,
,},
Fei MI^{1, 2
,
,}

1.
Yunnan Provincial Key Laboratory of Public Health and Biosafety，Kunming Yunnan 650500
2.
School of Public Health，Kunming Medical University，Kunming Yunnan 650500，China

Received Date: 2025-02-15
Publish Date: 2025-07-21

Abstract

Abstract

Metabolic dysfunction-associated steatotic liver disease （MASLD） is a chronic liver condition intricately linked to metabolic abnormalities such as obesity, type 2 diabetes, dyslipidemia, and hypertension. The global prevalence of MASLD continues to rise, posing a significant public health challenge.The pathogenesis of MASLD is multifactorial, with the "multiple-hit" hypothesis suggesting that hepatic lipid accumulation, insulin resistance, oxidative stress, gut microbiota dysbiosis, and genetic factors collectively drive disease progression. Currently, clinical management primarily relies on lifestyle interventions; however, there is a lack of targeted pharmacological interventions, and there is an urgent need to investigate novel adjunctive therapeutic strategies. In recent years, probiotics have demonstrated potential value in MASLD treatment due to their capacity to modulate gut microbiota, enhance insulin sensitivity, and reduce liver inflammation. This review systematically examines the pathogenesis of MASLD and the limitations of existing therapeutic approaches, synthesizing the latest evidence of probiotics-assisted therapy for MASLD from the perspectives of animal studies and clinical trials.By analyzing the target mechanisms and molecular pathways of different strains （e.g., Bifidobacterium, Lactobacillus）, this review explores the translational potential of probiotics in MASLD treatment, aiming to provide a theoretical foundation and future research directions.
- MASLD,
- Pathogenic mechanism,
- Probiotics,
- Adjunctive therapy

FullText(HTML)

References(78)

References

[1]	Poniachik J,Roblero J P,Urzúa A,et al. A new definition for non-alcoholic fatty liver disease[J]. J Hepatol,2021,74(4):982-983. doi: 10.1016/j.jhep.2020.09.002
[2]	Cotter T G,Rinella M. Nonalcoholic fatty liver disease 2020: The state of the disease[J]. Gastroenterology,2020,158(7):1851-1864. doi: 10.1053/j.gastro.2020.01.052
[3]	Scapaticci S,D’ Adamo E,Mohn A,et al. Non-alcoholic fatty liver disease in obese youth with insulin resistance and type 2 diabetes[J]. Front Endocrinol(Lausanne),2021,12:639548. doi: 10.3389/fendo.2021.639548
[4]	Pafili K,Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans[J]. Mol Metab,2021,50:101122.
[5]	Wang C,Zhu C,Shao L,et al. Role of bile acids in dysbiosis and treatment of nonalcoholic fatty liver disease[J]. Mediators Inflamm,2019,2019:7659509.
[6]	De Munck T J I,Xu P,Verwijs H J A,et al. Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Liver Int,2020,40(12):2906-2916. doi: 10.1111/liv.14696
[7]	Han H,Jiang Y,Wang M,et al. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): Focusing on the gut-liver axis[J]. Crit Rev Food Sci Nutr,2023,63(12):1689-1706. doi: 10.1080/10408398.2021.1966738
[8]	Quek J,Chan K E,Wong Z Y,et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2023,8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X
[9]	Vilar-Gomez E,Martinez-Perez Y,Calzadilla-Bertot L,et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis [J]. Gastroenterology,2015,149(2): 367-378. e5.
[10]	Kandel A,Pant P,Todi S,et al. Effect of exercise and pharmacotherapy on non-alcoholic fatty liver disease[J]. SAGE Open Med,2024,12:20503121241227090.
[11]	Abdel-Razik A,Mousa N,Shabana W,et al. Rifaximin in nonalcoholic fatty liver disease: Hit multiple targets with a single shot[J]. Eur J Gastroenterol Hepatol,2018,30(10):1237-1246. doi: 10.1097/MEG.0000000000001232
[12]	Li K P,Yu Y,Yuan M,et al. Tian-Huang formula,a traditional Chinese medicinal prescription,improves hepatosteatosis and glucose intolerance targeting AKT-SREBP nexus in diet-induced obese rats[J]. Evid Based Complement Alternat Med,2021,2021:6617586.
[13]	Ji L,Li Q,He Y,et al. Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug Potentilla discolor Bunge[J]. Acta Pharm Sin B,2022,12(9):3529-3547. doi: 10.1016/j.apsb.2022.05.001
[14]	Shou D,Luo Q,Tang W,et al. Hepatobiliary and pancreatic: Multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota[J]. J Gastroenterol Hepatol,2023,38(12):2195-2205. doi: 10.1111/jgh.16359
[15]	Witjes J J,Smits L P,Pekmez C T,et al. Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis[J]. Hepatol Commun,2020,4(11):1578-1590. doi: 10.1002/hep4.1601
[16]	Craven L,Rahman A,Nair Parvathy S,et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial[J]. Am J Gastroenterol,2020,115(7):1055-1065. doi: 10.14309/ajg.0000000000000661
[17]	Xue L,Deng Z,Luo W,et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial[J]. Front Cell Infect Microbiol,2022,12:759306. doi: 10.3389/fcimb.2022.759306
[18]	Yu Q,Wu L,Ji J,et al. Gut microbiota,peroxisome proliferator-activated receptors,and hepatocellular carcinoma[J]. J Hepatocell Carcinoma,2020,7:271-288. doi: 10.2147/JHC.S277870
[19]	Zaharuddin L,Mokhtar N M,Muhammad Nawawi K N,et al. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer[J]. BMC Gastroenterol,2019,19(1):131. doi: 10.1186/s12876-019-1047-4
[20]	Yan Y,Liu C,Zhao S,et al. Probiotic Bifidobacterium lactis V9 attenuates hepatic steatosis and inflammation in rats with non-alcoholic fatty liver disease[J]. AMB Express,2020,10(1):101. doi: 10.1186/s13568-020-01038-y
[21]	Lv H,Tao F,Peng L,et al. In vitro probiotic properties of Bifidobacterium animalis subsp. lactis SF and its alleviating effect on non-alcoholic fatty liver disease[J]. Nutrients,2023,15(6):1355. doi: 10.3390/nu15061355
[22]	Meybodi S M,Rezazadeh Khabaz M J,Vojdani A,et al. Bifidobacterium adolescentis prevents diabetes-induced liver injury via pyroptosis attenuation[J]. Exp Cell Res,2025,447(2):114518. doi: 10.1016/j.yexcr.2025.114518
[23]	Tian C,Deng S,Zhang Z,et al. Bifidobacterium bifidum 1007478 derived indole-3-lactic acid alleviates NASH via an aromatic hydrocarbon receptor-dependent pathway in zebrafish[J]. Life Sci,2025,369:123557. doi: 10.1016/j.lfs.2025.123557
[24]	Machado A S,Oliveira J R,Lelis D F,et al. Oral probiotic Bifidobacterium longum supplementation improves metabolic parameters and alters the expression of the renin-angiotensin system in obese mice liver[J]. Biol Res Nurs,2021,23(1):100-108. doi: 10.1177/1099800420942942
[25]	Do M H,Oh M J,Lee H B,et al. Bifidobacterium animalis ssp. lactis MG741 reduces body weight and ameliorates nonalcoholic fatty liver disease via improving the gut permeability and amelioration of inflammatory cytokines[J]. Nutrients,2022,14(9):1965. doi: 10.3390/nu14091965
[26]	Song Q,Zhang X,Liu W,et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma[J]. J Hepatol,2023,79(6):1352-1365. doi: 10.1016/j.jhep.2023.07.005
[27]	Bakhshimoghaddam F,Shateri K,Sina M,et al. Daily consumption of synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial[J]. J Nutr,2018,148(8):1276-1284. doi: 10.1093/jn/nxy088
[28]	Malaguarnera M,Vacante M,Antic T,et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]. Dig Dis Sci,2012,57(2):545-553. doi: 10.1007/s10620-011-1887-4
[29]	Scorletti E,Afolabi P R,Miles E A,et al. Synbiotics alter fecal microbiomes,but not liver fat or fibrosis,in a randomized trial of patients with nonalcoholic fatty liver disease [J]. Gastroenterology,2020,158(6): 1597-1610. e7.
[30]	Luo M,Yan J,Wu L,et al. Probiotics alleviated nonalcoholic fatty liver disease in high-fat diet-fed rats via gut microbiota/FXR/FGF15 signaling pathway[J]. J Immunol Res,2021,2021:2264737.
[31]	Wang W,Li Q,Chai W,et al. Lactobacillus paracasei Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease[J]. Food Sci Nutr,2019,7(8):2636-2646. doi: 10.1002/fsn3.1118
[32]	Kim S W,Park K Y,Kim B,et al. Lactobacillus rhamnosus GG improves insulin sensitivity and reduces adiposity in high-fat diet-fed mice through enhancement of adiponectin production[J]. Biochem Biophys Res Commun,2013,431(2):258-263. doi: 10.1016/j.bbrc.2012.12.121
[33]	Kim B,Park K Y,Ji Y,et al. Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice[J]. Biochem Biophys Res Commun,2016,473(2):530-536. doi: 10.1016/j.bbrc.2016.03.107
[34]	Bajaj J S,Heuman D M,Hylemon P B,et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome,metabolome and endotoxemia in patients with cirrhosis[J]. Aliment Pharmacol Ther,2014,39(10):1113-1125. doi: 10.1111/apt.12695
[35]	Li C,Nie S P,Zhu K X,et al. Lactobacillus plantarum NCU116 improves liver function,oxidative stress and lipid metabolism in rats with high fat diet induced non-alcoholic fatty liver disease[J]. Food Funct,2014,5(12):3216-3223. doi: 10.1039/C4FO00549J
[36]	Chen M,Guo W L,Li Q Y,et al. The protective mechanism of Lactobacillus plantarum FZU3013 against non-alcoholic fatty liver associated with hyperlipidemia in mice fed a high-fat diet[J]. Food Funct,2020,11(4):3316-3331. doi: 10.1039/C9FO03003D
[37]	Yao F,Jia R,Huang H,et al. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease[J]. Arch Med Sci,2019,15(5):1336-1344. doi: 10.5114/aoms.2019.86611
[38]	Nguyen H T,Gu M,Werlinger P,et al. Lactobacillus sakei MJM60958 as a potential probiotic alleviated non-alcoholic fatty liver disease in mice fed a high-fat diet by modulating lipid metabolism,inflammation,and gut microbiota[J]. Int J Mol Sci,2022,23(21):13436. doi: 10.3390/ijms232113436
[39]	Song W,Wang T,Cui X,et al. Lactobacillus coryniformis subsp. torquens T3 alleviates non-alcoholic fatty liver disease via reconstruction of the gut microbiota and redox system[J]. J Sci Food Agric,2023,103(14):6814-6825. doi: 10.1002/jsfa.12774
[40]	Ferolla S M,Couto C A,Costa-Silva L,et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters,but not on gut permeability in a population with nonalcoholic steatohepatitis[J]. Nutrients,2016,8(7):E397. doi: 10.3390/nu8070397
[41]	Jang H R,Park H J,Kang D,et al. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption[J]. Exp Mol Med,2019,51(8):1-14.
[42]	Mu J,Tan F,Zhou X,et al. Lactobacillus fermentum CQPC06 in naturally fermented pickles prevents non-alcoholic fatty liver disease by stabilizing the gut-liver axis in mice[J]. Food Funct,2020,11(10):8707-8723. doi: 10.1039/D0FO01823F
[43]	Yoon Y,Kim G,Noh M G,et al. Lactobacillus fermentum promotes adipose tissue oxidative phosphorylation to protect against diet-induced obesity[J]. Exp Mol Med,2020,52(9):1574-1586. doi: 10.1038/s12276-020-00502-w
[44]	Zhu C,Guan Q,Song C,et al. Regulatory effects of Lactobacillus fermented black barley on intestinal microbiota of NAFLD rats[J]. Food Res Int,2021,147:110467. doi: 10.1016/j.foodres.2021.110467
[45]	Lee N Y,Shin M J,Youn G S,et al. Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis[J]. Clin Mol Hepatol,2021,27(1):110-124. doi: 10.3350/cmh.2020.0125
[46]	Werlinger P,Nguyen H T,Gu M,et al. Lactobacillus reuteri MJM60668 prevent progression of non-alcoholic fatty liver disease through anti-adipogenesis and anti-inflammatory pathway[J]. Microorganisms,2022,10(11):2203. doi: 10.3390/microorganisms10112203
[47]	Choi S I,You S,Kim S,et al. Weissella cibaria MG5285 and Lactobacillus reuteri MG5149 attenuated fat accumulation in adipose and hepatic steatosis in high-fat diet-induced C57BL/6J obese mice[J]. Food Nutr Res,2021,65:8087.
[48]	Zhou L,Gong L,Liu Z,et al. Probiotic interventions with highly acid-tolerant Levilactobacillus brevis strains improve lipid metabolism and gut microbial balance in obese mice[J]. Food Funct,2025,16(1):112-132. doi: 10.1039/D4FO03417A
[49]	Kim H,Jeon H J,Jeong J W,et al. Lactobacillus helveticus HY7804 modulates the gut-liver axis to improve metabolic dysfunction-associated steatotic liver disease in a mouse model[J]. Int J Mol Sci,2025,26(8):3557.
[50]	Abdel Monem S M. Probiotic therapy in patients with nonalcoholic steatohepatitis in zagazig university hospitals[J]. Euroasian J Hepatogastroenterol,2017,7(1):101-106.
[51]	Vajro P,Mandato C,Licenziati M R,et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease[J]. J Pediatr Gastroenterol Nutr,2011,52(6):740-743. doi: 10.1097/MPG.0b013e31821f9b85
[52]	Endo H,Niioka M,Kobayashi N,et al. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: New insight into the probiotics for the gut-liver axis[J]. PLoS One,2013,8(5):e63388. doi: 10.1371/journal.pone.0063388
[53]	Zhou D,Pan Q,Liu X L,et al. Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation[J]. J Gastroenterol Hepatol,2017,32(9):1640-1648. doi: 10.1111/jgh.13742
[54]	Yang T,Yang H,Heng C,et al. Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice[J]. Food Funct,2020,11(12):10675-10689. doi: 10.1039/D0FO01954B
[55]	Zhu W,Yan M,Cao H,et al. Effects of Clostridium butyricum capsules combined with rosuvastatin on intestinal flora,lipid metabolism,liver function and inflammation in NAFLD patients[J]. Cell Mol Biol(Noisy-le-grand),2022,68(2):64-69. doi: 10.14715/cmb/2022.68.2.10
[56]	Kim B,Kwon J,Kim M S,et al. Protective effects of Bacillus probiotics against high-fat diet-induced metabolic disorders in mice[J]. PLoS One,2018,13(12):e0210120. doi: 10.1371/journal.pone.0210120
[57]	Abhari K,Saadati S,Yari Z,et al. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized,placebo-controlled,clinical trial[J]. Clin Nutr ESPEN,2020,39:53-60. doi: 10.1016/j.clnesp.2020.06.020
[58]	Keshavarz Azizi Raftar S,Ashrafian F,Yadegar A,et al. The protective effects of live and pasteurized Akkermansia muciniphila and its extracellular vesicles against HFD/CCl₄-induced liver injury[J]. Microbiol Spectr,2021,9(2):e0048421. doi: 10.1128/Spectrum.00484-21
[59]	Kim S,Lee Y,Kim Y,et al. Akkermansia muciniphila prevents fatty liver disease,decreases serum triglycerides,and maintains gut homeostasis[J]. Appl Environ Microbiol,2020,86(7):e03004-19.
[60]	Hu W,Gao W,Liu Z,et al. Specific strains of Faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation[J]. Nutrients,2022,14(14):2945. doi: 10.3390/nu14142945
[61]	Juárez-Fernández M,Porras D,Petrov P,et al. The synbiotic combination of Akkermansia muciniphila and quercetin ameliorates early obesity and NAFLD through gut microbiota reshaping and bile acid metabolism modulation[J]. Antioxidants(Basel),2021,10(12):2001. doi: 10.3390/antiox10122001
[62]	Nian F,Wu L,Xia Q,et al. Akkermansia muciniphila and Bifidobacterium bifidum prevent NAFLD by regulating FXR expression and gut microbiota[J]. J Clin Transl Hepatol,2023,11(4):763-776.
[63]	Depommier C,Everard A,Druart C,et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study[J]. Nat Med,2019,25(7):1096-1103.
[64]	Raftar S K A,Ashrafian F,Abdollahiyan S,et al. The anti-inflammatory effects of Akkermansia muciniphila and its derivates in HFD/CCL4-induced murine model of liver injury[J]. Sci Rep,2022,12(1):2453. doi: 10.1038/s41598-022-06414-1
[65]	Li T,Lin X,Shen B,et al. Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells[J]. Front Immunol,2022,13:1047570. doi: 10.3389/fimmu.2022.1047570
[66]	Han Y,Ling Q,Wu L,et al. Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization[J]. Gut Microbes,2023,15(1):2221485. doi: 10.1080/19490976.2023.2221485
[67]	Shin J H,Lee Y,Song E J,et al. Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet[J]. Front Microbiol,2023,14:1123547. doi: 10.3389/fmicb.2023.1123547
[68]	Liang Y,Lin C,Zhang Y,et al. Probiotic mixture of Lactobacillus and Bifidobacterium alleviates systemic adiposity and inflammation in non-alcoholic fatty liver disease rats through Gpr109a and the commensal metabolite butyrate[J]. Inflammopharmacology,2018,26(4):1051-1055. doi: 10.1007/s10787-018-0479-8
[69]	Behrouz V,Aryaeian N,Zahedi M J,et al. Effects of probiotic and prebiotic supplementation on metabolic parameters,liver aminotransferases,and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial[J]. J Food Sci,2020,85(10):3611-3617. doi: 10.1111/1750-3841.15367
[70]	Mohamad Nor M H,Ayob N,Mokhtar N M,et al. The effect of probiotics (MCP® BCMC® strains) on hepatic steatosis,small intestinal mucosal immune function,and intestinal barrier in patients with non-alcoholic fatty liver disease[J]. Nutrients,2021,13(9):3192. doi: 10.3390/nu13093192
[71]	Ayob N,Muhammad Nawawi K N,Mohamad Nor M H,et al. The effects of probiotics on small intestinal microbiota composition,inflammatory cytokines and intestinal permeability in patients with non-alcoholic fatty liver disease[J]. Biomedicines,2023,11(2):640. doi: 10.3390/biomedicines11020640
[72]	Cai G S,Su H,Zhang J. Protective effect of probiotics in patients with non-alcoholic fatty liver disease[J]. Medicine(Baltimore),2020,99(32):e21464. doi: 10.1097/MD.0000000000021464
[73]	Crommen S,Rheinwalt K P,Plamper A,et al. A specifically tailored multistrain probiotic and micronutrient mixture affects nonalcoholic fatty liver disease-Related markers in patients with obesity after mini gastric bypass surgery[J]. J Nutr,2022,152(2):408-418. doi: 10.1093/jn/nxab392
[74]	Escouto G S,Port G Z,Tovo C V,et al. Probiotic supplementation,hepatic fibrosis,and the microbiota profile in patients with nonalcoholic steatohepatitis: A randomized controlled trial[J]. J Nutr,2023,153(7):1984-1993. doi: 10.1016/j.tjnut.2023.05.019
[75]	Barcelos S T A,Silva-Sperb A S,Moraes H A,et al. Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study[J]. Ann Hepatol,2023,28(1):100769. doi: 10.1016/j.aohep.2022.100769
[76]	Derosa G,Guasti L,D'Angelo A,et al. Probiotic therapy with VSL#3® in patients with NAFLD: A randomized clinical trial[J]. Front Nutr,2022,9:846873. doi: 10.3389/fnut.2022.846873
[77]	Chong P L,Laight D,Aspinall R J,et al. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease[J]. BMC Gastroenterol,2021,21(1):144. doi: 10.1186/s12876-021-01660-5
[78]	Augustijn Q J J,Grefhorst A,de Groen P,et al. Randomised double-blind placebo-controlled trial protocol to evaluate the therapeutic efficacy of lyophilised faecal microbiota capsules amended with next-generation beneficial bacteria in individuals with metabolic dysfunction-associated steatohepatitis[J]. BMJ Open,2025,15(1):e088290. doi: 10.1136/bmjopen-2024-088290

Relative Articles(20)

Relative Articles

[1]	Menghuan LI, Li AI, Yongxia LI. Single-cell RNA Sequencing: A New Perspective in the Study of Chronic Obstructive Pulmonary Disease. Journal of Kunming Medical University, 2025, 46(3): 1-6. doi: 10.12259/j.issn.2095-610X.S20250301
[2]	Yichao JIN, Xiaochuan WANG, Chunping AO, Liangheng XU. Pruritus in Keloid：Pathogenesis and Treatments. Journal of Kunming Medical University, 2024, 45(12): 167-171. doi: 10.12259/j.issn.2095-610X.S20241224
[3]	Guojing LIANG, Kun JI, Kaichun ZHANG, Yufang ZHANG, Jing AN, Yuge ZHANG, Juan WEN, Haiyan REN. The Effect of Probiotics on the Expression of Aβ and the Protective Effect of Neurons in Rats with Cerebral Ischemia-Reperfusion Injury. Journal of Kunming Medical University, 2024, 45(5): 37-43. doi: 10.12259/j.issn.2095-610X.S20240506
[4]	Leijing RAN, Shaohua WANG, Lintong LI, Li GUI. A Meta-analysis of the Effect of Adjuvant Probiotics in Patients with Osteoporosis. Journal of Kunming Medical University, 2024, 45(2): 65-76. doi: 10.12259/j.issn.2095-610X.S20240209
[5]	Huawei JIANG, Xia LIU, Yan WANG, Minhui ZHANG, Weidan YIN, Liwei ZHANG. Research Progress on the Pathogenesis of Pterygium. Journal of Kunming Medical University, 2023, 44(1): 144-150. doi: 10.12259/j.issn.2095-610X.S20230125
[6]	Shunhang YANG, Jiongming LI, Jianhe LIU, Guang WANG, Pei LI. Progress in Pathogenesis and Treatment of Enteric Hyperoxaluria. Journal of Kunming Medical University, 2022, 43(7): 152-155. doi: 10.12259/j.issn.2095-610X.S20220734
[7]	Cuiling WU, Hongyi LIU, Yuan FAN, Jiarui LIU. Research Progress in Pathogenesis of Diabetic Encephalopathy. Journal of Kunming Medical University, 2022, 43(7): 145-151. doi: 10.12259/j.issn.2095-610X.S20220733
[8]	Yong-fang XU, Na WU, Yue-xin HU, Yong-mei ZHAO, Shao-ding ZHENG, Ling WEI, Si-jia ZHENG, Jian-jun LIU. Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats. Journal of Kunming Medical University, 2021, 42(8): 17-22. doi: 10.12259/j.issn.2095-610X.S20210804
[9]	Xing LIU, Hai-wen LI, Hong-li HUANG, Lin-jun SHEN, Le ZHANG, Xiang-fang LIU, Wen-lin ZHANG, Lu WANG. Effects of Probiotics Enhanced Enteral Nutrition on Gastrointestinal Function and Cytokines in Patients with Severe Acute Pancreatitis. Journal of Kunming Medical University, 2021, 42(11): 81-86. doi: 10.12259/j.issn.2095-610X.S20211116
[10]	Ze-xi LIN, Li-qing LIN, Jian-ren WANG, Tao XIE, Xi-an FU, Jun PU. Effects of Probiotics Enteral Nutrition on Ventilator Associated Pneumonia in Patients with Severe Brain Injury. Journal of Kunming Medical University, 2021, 42(12): 17-22. doi: 10.12259/j.issn.2095-610X.S20211213
[11]	Yang Huai Yong , Li Lin Da . . Journal of Kunming Medical University, 2020, 41(04): 111-116.
[12]	Liu Juan , Zhang Xiao Mei , Zhang Fan , Yang Chun Yan , Li Na , Tian Ying . . Journal of Kunming Medical University, 2020, 41(04): 64-68.
[13]	Liu Hua , Yue Wan Yuan , Luo Qi , Shao Shuai , Zhang Liang , Dai Xiao Ming . . Journal of Kunming Medical University, 2019, 40(11): 30-33.
[14]	Liang Cuan Yue , Guo Hao . . Journal of Kunming Medical University, 2019, 40(10): 165-170.
[15]	Qin Yuan , Yang Ying . . Journal of Kunming Medical University, 2019, 40(09): 125-129.
[16]	Li DongLin , Wu Wen Juan , Zou Dan Dan , He Li . . Journal of Kunming Medical University, 2018, 39(10): 1-6.
[17]	Li Wen Hua , Wei Yun Hong , Ye Ji Yun . Effect of Probiotics on Blood Lipid Metabolism of Elderly Patients with Coronary Heart Disease. Journal of Kunming Medical University, 2016, 37(12): 82-84.
[18]	Yang Zai Ying . The Effect of Osteoporosis on the Pathogenesis of Osteoarthritis. Journal of Kunming Medical University,
[19]	Zhang Yang . . Journal of Kunming Medical University,
[20]	Xiong Yan . . Journal of Kunming Medical University,